• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Antibiotics - Articles and news items

antibiotics resistance

Antibiotics: resist the resistance

Blog, Z Homepage promo / 15 September 2016 / Niamh Louise Marriott, Digital Content Producer

European Pharmaceutical Review caught up with Destiny Pharma’s CEO, Dr Love, for an exclusive interview to discuss why the pharmaceutical industry needs to radically change its approach to antibiotics in order to combat the threat of bacterial resistance…

antibiotics

Alliance to Save our Antibiotics: antimicrobial resistance ‘to kill one person every 3 seconds by 2050’

Blog / 13 September 2016 / Niamh Louise Marriott, Digital Content Producer

Following an article about the worrying presence of E.coli in UK supermarkets, our sister title New Food caught up with Emma Rose from Alliance to Save Our Antibiotics for an exclusive interview discussing the latest issues facing antibiotic resistance…

SA-ANTIBIOTIC-RESISTANCE

Destiny’s SA trial shows fast acting antibiotic too quick for disease resistance

Industry news / 5 September 2016 / Niamh Louise Marriott, Digital Content Producer

The two-stage clinical trial studied the safety, tolerability, and efficacy of intra-nasally applied exeporfinium chloride gels. Part 1 yielded safety data in eight volunteers and allowed progression to Part 2 in 48 healthy volunteers with colonised nasal Staphylococcus aureus (SA) bacteria. Part 2 was double-blinded, placebo controlled, and investigated two exeporfinium chloride concentration gels (0.5 & 2.0mg/g) and two viscosities (2% and 4%) applied into the nostrils for 5 days…

PnuBioVax

Pneumococcal vaccine PnuBioVax safe and immunogenic in Phase I study

Industry news / 30 June 2016 / Victoria White, Digital Content Producer

ImmBio has reported positive results from the First-in-Human study of its novel vaccine, PnuBioVax, against the bacterial pathogen Streptococcus pneumoniae…

Antibiotics resistance Q&A

Antibiotics resistance Q&A

Issue 3 2016 / 30 June 2016 / Caroline Richards

With the rise in drug-resistant bacterial infections heralding a new, dark era of medicine, antibiotics alternatives could one day become the first-line defence against infectious diseases. With the urgent need to find new approaches clear, Caroline Richards, Editor of European Pharmaceutical Review, interviewed Dr. Bjorn Herpers, Chief Medical Advisor of the Dutch biotechnology firm Micreos, to find out more about the company’s targeted antibacterial products. Micreos is developing a lysin called Staphefekt, which specifically targets Staphylococcus aureus, including meticillin-resistant Staphylococcus aureus (MRSA). Dr. Bjorn also serves as Clinical Microbiologist at Public Health Laboratory, Kennemerland…

Zavicefta

AstraZeneca’s new antibiotic Zavicefta approved in the EU

Industry news / 28 June 2016 / Victoria White, Digital Content Producer

The EC has granted marketing authorisation for Zavicefta for the treatment of patients with serious Gram-negative bacterial infections…

relebactam

Phase II study of relebactam in UTIs meets primary endpoint

Industry news / 21 June 2016 / Victoria White, Digital Content Producer

The addition of relebactam is designed to restore activity of imipenem against certain imipenem-resistant strains of Gram-negative bacteria…

AAI202

Allecra Therapeutics closes €22 Million Series B financing round

Industry news / 15 June 2016 / Victoria White, Digital Content Producer

The proceeds will fund Phase II development of AAI202 – a novel antibiotic combination designed to treat drug-resistant Gram-negative bacterial infections…

helperby

Helperby’s new approach to fighting resistant bacteria

Industry news / 23 May 2016 / Victoria White, Digital Content Producer

Helperby is about to begin clinical studies of a completely new approach to fighting resistant bacteria following a positive meeting with the FDA…

idr

Soligenix on IDR technology and SGX942

Blog / 10 May 2016 / Victoria White, Digital Content Producer

We discuss Innate Defense Regulator (IDR) technology with Soligenix’s Chief Scientific Officer, Dr Oreola Donini, and find out more about SGX942…

MGB-BP-3

MGB Biopharma and FDA discuss MGB-BP-3 regulatory strategy

Industry news / 9 May 2016 / Victoria White, Digital Content Producer

MGB Biopharma presented Phase I and preclinical data together with a proposal for the further development of oral MGB-BP-3 in C. difficile infections…

antibiotics

The threat of antibiotic resistance

Blog, Z Homepage promo / 27 April 2016 / Victoria White, Digital Content Producer

We’ve created an infographic on the threat of antibiotic resistance, highlighting some of the recommendations made by the Review on AMR…

 

Webinar: Different thermal analysis techniques to measure the glass transitionWATCH NOW
+ +